RNA editing is one of biology’s most elegant post-transcriptional tricks. Enzymes called adenosine deaminases acting on RNA, or ADARs, chemically convert adenosine bases in RNA molecules into inosine. Because the cell’s molecular machinery reads inosine as guanosine, this edit can rewrite the sequence of an RNA transcript without touching the underlying DNA. For protein-coding messenger RNAs, that can mean a subtly altered protein. But for microRNAs, the short non-coding strands that silence genes by binding to messenger RNA targets, an edit in the seed region, the critical stretch of about six to eight nucleotides that determines target recognition, can completely rewire which genes the microRNA represses.

The team focused on miR-376a-3p because it belongs to the miR-376 cluster, a family of microRNAs already known to be heavily edited in human tissues and previously implicated in cancers ranging from glioblastoma to prostate and esophageal tumors. Earlier work had shown that attenuated editing of miR-376a promotes invasiveness in glioblastoma cells, while edited versions of related microRNAs can either suppress or promote tumor growth depending on context. What remained unclear was what editing does to this particular microRNA in thyroid cancer, a disease often described as clinically inert but which nonetheless affects a growing number of patients worldwide.

To answer that question, the researchers first measured editing levels in papillary thyroid carcinoma (PTC) tissues and found them significantly elevated compared with non-cancerous thyroid tissue. They then hunted for the enzyme responsible. Among the ADAR family members, ADAR2, encoded by the gene ADARB1, emerged as the principal editor driving the modification of miR-376a-3p in PTC cells, and its activity was found to contribute to the carcinogenic process itself. That detail matters because it links a specific editing enzyme, a specific edited microRNA, and a specific cancer type into one coherent mechanistic chain.

The functional experiments were extensive. Using RT-qPCR, Western blotting, and immunohistochemistry, the team quantified microRNA and gene expression in patient tissues and cell lines. They then probed cancer-relevant behaviors with a battery of assays: CCK-8 and colony formation tests for proliferation, 5-ethynyl-2′-deoxyuridine (EdU) incorporation to track DNA synthesis, wound healing and Transwell assays to measure migration and invasion, and flow cytometry to profile cell death and cell-cycle effects. Across these readouts, a clear pattern emerged: the unedited, wild-type miR-376a-3p restrained malignant behavior, while the edited version, ed-miR-376a-3p, encouraged it. In other words, the same molecule, differing by a single inosine, played opposite roles depending on its editing state.

The molecular explanation lies in a target swap. MicroRNAs silence genes by base-pairing with complementary sequences in target messenger RNAs, and even one changed base in the seed region can abolish old partnerships and create new ones. Using dual-luciferase reporter assays, which test whether a microRNA can directly bind and suppress a predicted target sequence, the researchers showed that editing caused miR-376a-3p to lose its interaction with KPNA4, a gene previously linked to malignant phenotypes in papillary thyroid cancer, while simultaneously acquiring HOXD10 as a novel target. HOXD10 is a homeobox transcription factor with well-documented tumor-suppressive functions in multiple cancers, including earlier evidence of its silencing in thyroid tumors with BRAF V600E mutations.

With HOXD10 newly in its crosshairs, ed-miR-376a-3p suppresses the expression of this tumor suppressor, and the downstream consequence is metabolic. The team measured glycolytic activity through four independent readouts: glucose consumption, lactate production, extracellular acidification rate (ECAR), and oxygen consumption rate (OCR). Cancer cells famously favor glycolysis, the rapid fermentation of glucose into lactate even in the presence of oxygen, a phenomenon known as the Warburg effect, to fuel their growth. The experiments showed that ed-miR-376a-3p enhances glycolysis in PTC cells by downregulating HOXD10, thereby supplying the energy-hungry tumor with a more aggressive metabolic program.

This study adds to a growing body of evidence that A-to-I editing of microRNAs is a powerful and underappreciated layer of gene regulation in cancer. Recent work has documented edited microRNAs influencing tumor growth in esophageal squamous cell carcinoma, lung adenocarcinoma, and hepatocellular carcinoma, with editing sometimes restraining and sometimes accelerating disease. What makes the new finding particularly striking is the completeness of the mechanism: an elevated editing enzyme, a confirmed editing event in patient tumors, a demonstrated target switch verified by direct binding assays, and a metabolic endpoint that ties the whole cascade to tumor biology. Each link in the chain was tested experimentally rather than inferred from correlation alone.

The clinical implications are tantalizing, though the authors and the field caution that translating editing biology into therapy remains a distant goal. If editing levels of miR-376a-3p reliably mark more aggressive tumors, they could serve as biomarkers helping clinicians stratify patients with papillary thyroid cancer, most of whom have excellent prognoses but a subset of whom experience recurrence or metastasis. More ambitiously, the ADAR2-miR-376a-3p-HOXD10 axis offers multiple potential intervention points: inhibiting the editing enzyme, neutralizing the edited microRNA, or restoring HOXD10 function. None of these strategies is yet available in the clinic, and the study’s data, while mechanistically thorough, derive from cell lines, patient samples, and animal models conducted under approved ethical protocols rather than from therapeutic trials.

For now, the significance of the work is conceptual as much as practical. It underscores that the genome’s final instructions are not fixed at DNA but negotiated at the RNA level, one edited base at a time. A microRNA that polices tumor growth in its canonical form can become a metabolic saboteur after a visit from ADAR2, and the difference between the two states is a single inosine that most conventional genomic analyses would never register. As RNA editing maps of human tumors grow more detailed, findings like this one suggest that the editing landscape may hold both explanatory power for cancer’s origins and untapped opportunities for its treatment, particularly in cancers like papillary thyroid carcinoma that have long been dismissed as too quiet to reveal their secrets.

Subject of Research: ADAR2-mediated A-to-I RNA editing of miR-376a-3p and its role in papillary thyroid cancer tumorigenesis

Article Title: A-to-I editing modifies the target and role of miR-376a-3p in papillary thyroid cancer

Article References: Yan, X., Mao, X., Zhu, C., Lv, G., Geng, X., Wu, W., Ding, Y., Qin, S., Wang, X., Li, Y., & Fang, L. (2026). A-to-I editing modifies the target and role of miR-376a-3p in papillary thyroid cancer. 3 Biotech, 16(9), Article 400. https://doi.org/10.1007/s13205-026-04984-9

Image Credits: AI Generated

DOI: 10.1007/s13205-026-04984-9

Keywords: A-to-I RNA editing, miR-376a-3p, ADAR2, papillary thyroid cancer, HOXD10, KPNA4, glycolysis, microRNA, RNA modification, tumor suppressor, oncogene, Warburg effect